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February 2016 Abstracts S15I will discuss novel applications of the CRISPR/Cas9
for in vivo somatic editing. More speciﬁcally, I will pre-
sent data showing that in vivo delivery of pairs of guide
RNAs can be used to generate cancer-promoting chro-
mosomal rearrangements, enabling us to rapidly
generate more faithful mouse models of human cancers.
Lastly, I will discuss how we are applying this novel
technology for functional genomic screens aimed at
identifying cancer associated non-coding RNAs and DNA
regulatory elements.Intratumoral heterogeneity and
EGFR-TKIs resistanceCaicun Zhou, Weijing Cai Shanghai Pulmonary
Hospital; Tongji University Medical School
Pulmonary Cancer Institute, Shanghai, China
Lung cancer is one of the malignant tumors with the
highest degree of heterogeneity. Intratumoral hetero-
geneity includes histopathologic heterogeneity and ge-
netic heterogeneity. Intratumoral heterogeneity,
especially genetic heterogeneity, plays an important
role in resistance to targeted therapy. Some previous
studies have proved that Intratumoral heterogeneity is
one of the mechanism of EGFR-TKIs resistance in lung
cancer. The patients with NSCLC harboring T790Mmutation before targeted therapy had a poor response
to EGFR-TKIs. Besides, increasingly more lung cancers
were identiﬁed to harbor EGFR mutations and ALK
fusions concurrently with the development of gene
detection technology. Current studies on the explora-
tion of intratumoral heterogeneity did not go far
enough. Firstly, not all T790M or C797S mutations
which were identiﬁed in tumor cells after acquired
resistance were present due to treatment selection.
Secondly, the mechanism and treatment strategy for
lung cancer with dual altered driver remain contro-
versial. Finally, abundance of EGFR mutations caused
by intratumoral heterogeneity may affect the response
to EGFR-TKIs. Our team has done a lot of work on this
aspect. Our study identiﬁed intratumoral heterogeneity
in lung adenocarcinoma with dual oncogenic drivers. In
addition, we found patients with low abundance of EGFR
mutations had poor response to EGFR-TKIs. The ORR
for patients with high abundance of EGFR mutations
(HA-EGFR) was signiﬁcantly higher compared with
patients with low abundance of EGFR mutations
(LA-EGFR) (72.9% vs. 11.7%, P<0.001). The median PFS
in HA-EGFR group was also signiﬁcantly longer than
that in LA-EGFR group (19del subgroup: 15.0 vs 4.0
months, P<0.001; L858R subgroup: 12.0 vs 2.0,
P<0.001). In conclusion, intratumoral heterogeneity may
be an important reason for EGFR-TKIs resistance in lung
cancer.
